SCHEMBL537992

SCHEMBL537992

O=Cc1ccccc1CCc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.48
LMNA P02545 1/20 0.48
THRB P10828 1/20 0.48
BLM P54132 1/20 0.48
KMT2A Q03164 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
HTR1A P08908 1/20 0.44
DRD2 P14416 1/20 0.44
NR1H2 P55055 2/20 0.43
NR1H3 Q13133 1/20 0.43
ALDH1A1 P00352 4/20 0.42
ADRB2 P07550 1/20 0.42
MAPT P10636 1/20 0.41
HPGD P15428 2/20 0.41
HTT P42858 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
FFAR1 O14842 1/20 0.41
MAOA P21397 2/20 0.40
MAOB P27338 2/20 0.40
TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7091261 0.86 SIGMAR1 (0.50) MEN1LMNATHRBBLMKMT2A
Bromide SCHEMBL9225776 0.83 ABCB1 (0.46) MEN1LMNATHRBBLMKMT2A
SCHEMBL8406799 0.83 ERN1 (0.48) MEN1LMNATHRBBLMKMT2A
SCHEMBL872046 0.83 LMNA (0.52) MEN1LMNATHRBBLMKMT2A
SCHEMBL31588310 0.83 LMNA (0.52) MEN1LMNATHRBBLMKMT2A
SCHEMBL10685282 0.81 HTR1A (0.49) TDP1HTR1ADRD2ALDH1A1HTT
SCHEMBL9721777 0.79 KCNH2 (0.46) ALDH1A1HPGDHTR2AHSD17B10SIGMAR1
SCHEMBL5073359 0.79 MAPT (0.45) TDP1HTR1ADRD2NR1H2NR1H3
SCHEMBL14465961 0.78 LMNA (0.52) MEN1LMNATHRBBLMKMT2A
SCHEMBL9101479 0.78 HSD17B3 (0.48) TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023141855-A1 PROTEIN CONJUGATES WITH MULTIPLE PAYLOADS AND METHODS FOR MAKING THE SAME GLYCO-THERAPY BIOTECHNOLOGY CO., LTD. (CN) 2023-08-03 WO disclosed
US-20210300872-A1 SECOND GENERATION GRP94-SELECTIVE INHIBITORS UNIVERSITY OF KANSAS 2021-09-30 US disclosed
US-20200190017-A1 SECOND GENERATION GRP94-SELECTIVE INHIBITORS UNIVERSITY OF KANSAS 2020-06-18 US disclosed
US-8343961-B2 Substituted heterocyclic compounds ARQULE, INC. (US) 2013-01-01 US disclosed
US-8143288-B2 Inhibitors of HCV replication BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-27 US disclosed
EP-2414361-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS ArQule, Inc. (US) 2012-02-08 EP disclosed
WO-2010114894-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS ARQULE, INC. (US) 2010-10-07 WO disclosed
US-20100249115-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS ARQULE, INC. (US) 2010-09-30 US disclosed
CN-100360580-C Process for the solid phase synthesis of aldehyde, ketone, oxime, amine, hydroxamic acid and alpha, beta-unsaturated carboxylic acid and aldehyde compounds AVENTIS PHARM PROD INC (US) 2008-01-09 CN disclosed
CN-1769318-A Polymeric resin compounds and their preparation AVENTIS PHARM PROD INC (US) 2006-05-10 CN disclosed
US-4994539-A Ethylene-unsaturated aromatic copolymer NIPPON PETROCHEMICALS CO., LTD. (JP) 1991-02-19 US disclosed
EP-0180771-B1 METHOD FOR IMPROVING IMPULSE BREAKDOWN STRENGTH OF ELECTRICALLY INSULATING MATERIALS Nippon Petrochemicals Co., Ltd. (JP) 1989-08-02 EP disclosed
EP-0114385-B1 ELECTRICAL INSULATING OIL AND OIL-FILLED ELECTRICAL APPLIANCES NIPPON PETROCHEMICALS COMPANY, LIMITED (JP) 1987-08-05 EP disclosed
EP-0227487-A2 Positive type radiation-sensitive resin composition JAPAN SYNTHETIC RUBBER CO., LTD. (JP) 1987-07-01 EP disclosed
EP-0103868-B1 IMPROVED ELECTRICAL INSULATING OIL AND OIL-FILLED ELECTRICAL APPLIANCES NIPPON PETROCHEMICALS COMPANY, LIMITED (JP) 1987-04-08 EP disclosed
EP-0180771-A1 Method for improving impulse breakdown strength of electrically insulating materials Nippon Petrochemicals Co., Ltd. (JP) 1986-05-14 EP disclosed
US-4543207-A ORGANIC ACID ESTERS, AROMATIC ETHERS, ANIMAL OILS, VEGETABLE OILS,AND AROMATIC OLEFINS NIPPON PETROCHEMICALS COMPANY, LIMITED (JP) 1985-09-24 US disclosed
US-4493943-A MIXTURES OF DIARYLALKANES AND AROMATIC MONO-OR DI-OLEFINS NIPPON PETROCHEMICALS COMPANY, LIMITED (JP) 1985-01-15 US disclosed
EP-0114385-A2 Electrical insulating oil and oil-filled electrical appliances NIPPON PETROCHEMICALS COMPANY, LIMITED (JP) 1984-08-01 EP disclosed
EP-0103868-A2 Improved electrical insulating oil and oil-filled electrical appliances NIPPON PETROCHEMICALS COMPANY, LIMITED (JP) 1984-03-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249115-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS CYP11B2, GABBR1, CNR1 MEN1 402/4885LMNA 1273/4885THRB 2030/4885
US-20210300872-A1 SECOND GENERATION GRP94-SELECTIVE INHIBITORS HSP90B1, HSP90AB2P, HSPE1 MEN1 849/4885LMNA 3989/4885THRB 2726/4885
US-20200190017-A1 SECOND GENERATION GRP94-SELECTIVE INHIBITORS HSP90B1, HSP90AB2P, HSPE1 MEN1 853/4885LMNA 3960/4885THRB 2657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.